Compare · ADGM vs DXCM
ADGM vs DXCM
Side-by-side comparison of Adagio Medical Holdings Inc (ADGM) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ADGM and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $29.57B, about 1790.2x ADGM ($16.5M).
- Over the past year, ADGM is down 41.4% and DXCM is down 10.6% - DXCM leads by 30.8 points.
- DXCM has been more active in the news (26 items in the past 4 weeks vs 2 for ADGM).
- DXCM has more recent analyst coverage (25 ratings vs 2 for ADGM).
- Company
- Adagio Medical Holdings Inc
- DexCom Inc.
- Price
- $0.75-2.61%
- $76.59+5.15%
- Market cap
- $16.5M
- $29.57B
- 1M return
- -22.68%
- +25.71%
- 1Y return
- -41.41%
- -10.56%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 2
- 26
- Recent ratings
- 2
- 25
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest ADGM
- Adagio Medical Holdings Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Adagio Medical Submits Premarket Approval Application to FDA for vCLAS® Ventricular Ablation System for the Treatment of Ventricular Tachycardia
- Amendment: SEC Form SCHEDULE 13G/A filed by Adagio Medical Holdings Inc
- Amendment: SEC Form SCHEDULE 13G/A filed by Adagio Medical Holdings Inc
- SEC Form 10-Q filed by Adagio Medical Holdings Inc
- Adagio Medical Holdings Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form DEF 14A filed by Adagio Medical Holdings Inc
- Adagio Medical to Participate in the BofA Securities 2026 Health Care Conference
- Adagio Medical Holdings Inc filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Adagio Medical Announces Positive Pivotal Results for vCLAS® Ventricular Ablation System
Latest DXCM
- Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin
- EVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)
- Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026
- Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience
- Director Altman Steven R was granted 5,565 shares (SEC Form 4)
- Director Augustinos Nicholas was granted 5,575 shares (SEC Form 4)
- Director Malady Kyle was granted 5,575 shares, increasing direct ownership by 25% to 28,242 units (SEC Form 4)
- Director Heller Bridgette P was granted 5,575 shares, increasing direct ownership by 22% to 30,582 units (SEC Form 4)
- Director Osterloh Albert Frederick Iv was granted 1,630 shares, increasing direct ownership by 23% to 8,691 units (SEC Form 4)
- Director Foletta Mark G was granted 6,331 shares (SEC Form 4)